摘要
目的:探讨P-糖蛋白(P-gp)、肺耐药蛋白(LRP)、多药耐药相关蛋白(MRP)和谷光甘肽转移酶(GST-π)在非小细胞肺癌(NSCLC)中的表达及其临床意义。方法:应用免疫组织化学S-P技术对86例治疗前非小细胞肺癌组织标本进行P-gp、LRP、MRP和GST-π表达的检测。结果:LRP和MRP在肺腺癌、鳞癌中的表达阳性率分别为77.78%、51.22%和80.00%、53.66%;LRP和MRP在不同组织类型中的表达有显著性差异(均P<0.05)。P-gp和GST-π在肺腺癌和鳞癌中的表达阳性率分别为73.33%、60.98%和80.00%、70.73%;P-gp和GST-π在不同组织类型中的表达无显著性差异(均P>0.05)。所测4种耐药基因除P-gp外其余3种在中高分化和低分化组间表达阳性率有显著性差异(均P<0.01);4种耐药基因在TNM各分期中表达阳性率无显著性差异(均P>0.05)。在肺腺癌和肺鳞癌中同时有2种、3种或4种耐药基因协同表达的阳性率分别为46.67%和34.15%、31.11%和24.39%、20.00%和17.07%,在肺腺癌和肺鳞癌中耐药基因共表达在各类型间无显著性差异(均P>0.05)。结论:在非小细胞肺癌组织中存在不同程度的耐药,肺腺癌原发耐药高于肺鳞癌,其耐药是多途径多基因参与的过程。联合检测P-gp、LRP、MRP和GST-π耐药相关基因的表达,对化疗药物的选择及预后的评价具有重要的临床意义。
Objective :To investigate the expression level and clinical significance of P - gp, LRP, MRP and GST - π in non - small cell lung cancer tissues. Methods: The expression of P - Glycoprotein( P - gp) lung cancer resistance protein( LRP), muhidrug resistance protein (MRP) and glutathione S transferases (GST-π) were detected in 86 cases of lung cancer tissues from untreated patients by streptavidin - biotin - peroxidase ( S - P) immunohistochemistry technique. Results: The positive rates of LRP and MRP in the adenocarcinoma and squamous carcinoma were 77.78% ,51.22% and 80.00% ,53.66% respectively. There were statistic difference in LRP and MRP expression in different tissues types( All P 〈 0.05 ). The positive rates of P - gp and GST - π in the adenocarcinoma and squamous carcinoma were 73.33% ,60.98% and 80.00% ,70.73% respectively. No significant difference was ob- served among the positive rates of P-gp and GST- π in different types of lung cancer( All P 〉 0.05 ). There were statistic difference in the expression positive rates except P - gp in all detected four resistance - related genes between the higher and lower differentiated degree( All P 〈 0.05 ). No significant difference was observed among the positive rates of four resistance - related genes in different TNM staging of lung cancer ( All P 〉 0.05 ). Two kinds or three kinds or four kinds of resistance - related genes co - expression in the adenocarcinoma and squamous carcinoma tissues were 46.67% and 34.15% ,31.11% and 24.39% ,20.00% and 17.07% respectively. No significant difference was observed among the co - expression positive rates of various types in the adenocarcinoma and squamous carcinoma tissues ( All P 〉 0.05 ). Conclusion: It has different degree overexpression of resistance - related genes in NSCLC tissues,multidrug resistence in adenocarcinoma was higher than that in squamous carcinoma, MDR of lung cancer is a process involved in polygene and multiple pathways. Combined detection of P -gp, LRP, MRP and GST- π may be useful for guiding the clinical chemotherapy of lung cancer and judgement the prognosis.
出处
《现代肿瘤医学》
CAS
2009年第8期1444-1447,共4页
Journal of Modern Oncology
基金
河北省科技攻关课题(20042761599)
关键词
非小细胞肺癌
多药耐药
耐药基因
免疫组化
non - small cell lung cancer ( NSCLC )
multidrug resistance ( MDR )
resistance genes
immunohistochemistry